Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Recruitment challenges
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Usually the treatment of a single brain metastasis is surgery or Stereotactic Radiosurgery (SRS). Surgery involves resection of the brain tumor by means of an operation, whereas SRS is treatment consisting of highly focused radiation doses to the tumor. These two treatment modalities are both widely used, well established, and proven to improve survival, but so far, no study has been done to directly compare the efficacy of one over the other. Neither treatment in itself is considered to be experimental and both have been shown to provide benefits to patients with metastatic brain tumors. The aim of this study is to determine which two modalities are better for local control and improving quality of life.
Patients who consent to this study will be randomized to either receive surgery or Radiosurgery in the treatment of single brain metastases. The study seeks to recruit 12 patient to each group. Patients will be in this study for up to five years from the time of the treatment finished. This will include follow-up visits at 4 weeks after the procedure and then every 3 months after the procedure up to 5 years.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Radiosurgery (SRS) | Active Comparator |
| |
| Surgery | Active Comparator |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Surgery | Procedure | Prior to surgery, patients will have placement of scalp fiducials and undergo a contrast enhanced MRI scan. Once the patient is anesthetized or sedated, the head will be secured with a head frame and scalp fiducials will be registered to the stereotactic neuronavigation system. The tumor will then be resected and the patient will be taken to the recovery unit. |
| Measure | Description | Time Frame |
|---|---|---|
| To determine the feasibility of accrual to a randomized trial of SRS vs Surgery in patients with single brain metastasis. | 2 years | |
| To compare the incidence of recommendation for a second local therapeutic intervention to the treated metastasis at 1 year. | 2 years |
| Measure | Description | Time Frame |
|---|---|---|
| To compare overall survival between the two randomized cohorts. | 2 years | |
| To compare local-recurrence-free survival between the two randomized cohorts. | 2 years | |
Not provided
Inclusion Criteria:
Exclusion Criteria:
11.Allergy to Gadolinium 12.Imminent brain herniation, massive peritumoural oedema or hydrocephalus 13.Have any metallic implant that would exclude the possibility of having a brain MRI
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Gelareh Zadeh, MD | University Health Network, Toronoto Western Hospital | Principal Investigator |
Not provided
| ID | Term |
|---|---|
| D001932 | Brain Neoplasms |
| ID | Term |
|---|---|
| D016543 | Central Nervous System Neoplasms |
| D009423 | Nervous System Neoplasms |
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
Not provided
Not provided
| ID | Term |
|---|---|
| D013514 | Surgical Procedures, Operative |
| D016634 | Radiosurgery |
| ID | Term |
|---|---|
| D011878 | Radiotherapy |
| D013812 | Therapeutics |
| D013238 | Stereotaxic Techniques |
| D019635 | Neurosurgical Procedures |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Stereotactic Radiosurgery | Procedure | This will be delivered using Gamma Knife technology. Patients randomized to this arm will be fitted with a stereotactic head-frame for stereotactic localization of brain metastases. |
|
| To compare CTCAE v 3.0 neurological outcomes |
| 2 years |
| To evaluate difference in neurocognitive outcomes | 2 years |
| To measure and compare quality of life | 2 years |
| To determine adverse effects attributable to local therapy | 2 years |
| To compare medication requirements in each cohorts (steroids, anticonvulsants) | 2 years |
| To explore potential predictive factors of outcomes | 2 years |
| To investigate potential biofluid and imaging biomarkers of response | 2 years |
| To compare ECOG performance status | 2 years |
| D001927 |
| Brain Diseases |
| D002493 | Central Nervous System Diseases |
| D009422 | Nervous System Diseases |
| D008919 |
| Investigative Techniques |